WESTON, FLORIDA, USA, April 14, 2026
Apotex Corp., in collaboration with Orbicular Pharmaceutical Technologies Pvt. Ltd. and Gland Pharma Limited, has received U.S. FDA approval for two Abbreviated New Drug Applications (ANDA) for the first generic version of Infuvite® Adult Injection, including both single-dose vials and pharmacy bulk packages. Notably, the product has been granted 180-day Competitive Generic Therapy (CGT) exclusivity for the pharmacy bulk package, marking a significant milestone in the U.S. generic injectable market and reinforcing the importance of regulatory strategy, manufacturing excellence, and strategic partnerships in pharmaceutical development.
FDA Approval Strengthens Generic Injectable Portfolio
The FDA approval represents a major advancement in complex sterile injectable drug development, particularly for products used in parenteral nutrition. Infuvite® Adult Injection is a multivitamin formulation comprising 13 essential vitamins, widely used in hospital settings for patients requiring intravenous nutritional support. The approval of the generic version ensures increased accessibility, cost-effectiveness, and supply reliability in the healthcare system. Apotex, as the ANDA applicant, will lead commercialization efforts in the United States, leveraging its expertise in delivering high-quality generic medicines to a broad patient population.
CGT Exclusivity Highlights Regulatory and Market Advantage
The grant of 180-day CGT exclusivity provides Apotex with a temporary competitive advantage, allowing exclusive marketing of the pharmacy bulk package version before additional generic competitors enter the market. This designation underscores the value of the FDA’s Competitive Generic Therapy pathway, designed to encourage the development of generics in markets with limited competition. Achieving first-to-market status reflects the company’s strong regulatory execution and ability to navigate complex ANDA requirements, particularly for formulations involving multiple active ingredients and stringent stability considerations.
Advertisement
Collaborative Development Drives Technical and Manufacturing Success
The successful approval is the result of a multi-partner collaboration combining expertise across drug development, regulatory strategy, and commercial manufacturing. Orbicular Pharmaceutical Technologies played a key role in formulation development, analytical characterization, and stability engineering, ensuring compliance with evolving regulatory standards. Meanwhile, Gland Pharma contributed its advanced sterile injectable manufacturing capabilities, including the execution of validation batches and large-scale production readiness. This integrated approach highlights the importance of cross-functional collaboration in delivering complex pharmaceutical products, particularly in regulated markets requiring GMP-compliant manufacturing and rigorous quality controls.
Advancing Access to Critical Hospital Therapies
The approval of generic Infuvite® is expected to improve patient access to essential hospital therapies, particularly for individuals requiring intravenous nutritional supplementation. As healthcare systems increasingly focus on cost containment and supply chain resilience, the availability of high-quality generics plays a crucial role in ensuring continuity of care and treatment affordability. The development also reflects broader industry trends toward complex generics and value-driven pharmaceutical innovation, where companies are leveraging scientific and technical expertise to address unmet needs in established therapeutic areas.
The FDA approval of Apotex’s generic Infuvite® Adult Injection, coupled with 180-day CGT exclusivity, represents a significant achievement in the pharmaceutical generics landscape. By combining regulatory excellence, advanced formulation science, and robust manufacturing capabilities, the collaboration between Apotex, Orbicular, and Gland Pharma has successfully delivered a complex injectable product to market. This milestone reinforces the growing importance of strategic partnerships and innovation in generic drug development, ultimately supporting improved access to safe, effective, and affordable therapies for patients worldwide.
Source: Apotex press release
